Amarin (NASDAQ:AMRN - Get Free Report) is set to release its earnings data after the market closes on Wednesday, October 30th. Analysts expect Amarin to post earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Amarin Price Performance
Shares of AMRN remained flat at $0.58 during midday trading on Wednesday. The stock had a trading volume of 703,550 shares, compared to its average volume of 1,554,766. The company has a market capitalization of $237.57 million, a P/E ratio of -4.82 and a beta of 1.92. Amarin has a fifty-two week low of $0.57 and a fifty-two week high of $1.37. The firm has a 50 day moving average price of $0.60 and a 200 day moving average price of $0.73.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded shares of Amarin from a "buy" rating to a "hold" rating in a research report on Thursday, July 4th.
View Our Latest Stock Report on Amarin
Insider Activity at Amarin
In other news, CEO Aaron Berg acquired 160,000 shares of the business's stock in a transaction dated Friday, August 2nd. The shares were purchased at an average price of $0.64 per share, with a total value of $102,400.00. Following the transaction, the chief executive officer now directly owns 805,380 shares in the company, valued at approximately $515,443.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.96% of the stock is owned by corporate insiders.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
